Promising Outlook for Lexicon Pharmaceuticals’ LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic Pain
Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LXRX stock, giving a Buy rating yesterday.Invest with Confidence: ...
Neuropathic Pain Market Size, Growth & Forecast By 2033
Introduction Neuropathic pain is a persistent pain condition caused by nerve damage or dysfunction in the nervous system. It is distinct from n ...
GlobalData on MSN12d
FDA approves Vertex’s acute pain treatment Journavx
The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
pharmaphorum7d
Algiax non-opioid drug works in chronic neuropathic pain
The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...
Healthline12d
CBD for Nerve Pain: 5 Products to Try in 2025
Certain conditions, such as diabetes, may increase your risk of neuropathy, which could lead to neuropathic pain. CBD lotions, creams, and salves may help reduce aches and pains. It’s unclear ...
Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...